Vycor Medical, Inc. reported substantial increases in revenue and operating profit for the three and six months ended June 30, 2025, marking a period of significant growth for the company. The Vycor Medical division, known for its ViewSite™ Brain Access System (VBAS), saw revenues increase by 24% and 28% for the three and six months, respectively, compared to the same periods in 2024. This growth was largely attributed to the company's expansion into international markets, including new distribution agreements in France and Spain.
The company's operating profit for the three and six months ended June 30, 2025, was reported at $51,146 and $38,340, respectively, with non-GAAP operating profit figures reaching $84,481 and $106,944. These figures represent significant improvements over the previous year, underscoring the company's operational efficiency and market penetration strategies. Financial results for the period showed the company's revenue reaching $496,353 for the three months ended June 30, 2025, a 22% increase from the same period in 2024. The six-month revenue stood at $932,731, up 25% year-over-year.
Vycor Medical's commitment to innovation and clinical excellence was further highlighted by the publication of two new clinical papers on the VBAS system, bringing the total number of peer-reviewed clinical papers to 48. These studies, focusing on the use of tubular retractors in brain surgery and neuro-oncology surgery, reinforce the clinical advantages of the VBAS system. Additionally, a new study on NovaVision's NeuroEyeCoach program demonstrated its effectiveness in both home-based and clinic-based settings, aligning with global healthcare trends towards digital and remote therapeutic solutions.
The gross profit margin for 2025 was reported at 83%, slightly lower than the previous year's 91%, due to costs associated with new production validation and shipping, as well as changes in the geographical sales mix. Vycor Medical's achievements during the first half of 2025 not only demonstrate its financial growth but also its contribution to advancing medical technology and patient care. The company's focus on international expansion and the validation of its products through clinical research positions it as a leader in minimally invasive neurosurgical and therapeutic solutions. For more information on Vycor Medical's innovative products, visit https://www.vycormedical.com.
